Literature DB >> 24950234

Citicoline in addictive disorders: a review of the literature.

Nicholas D Wignall1, E Sherwood Brown.   

Abstract

BACKGROUND: Citicoline is a dietary supplement that has been used as a neuroprotective agent for neurological disorders such as stroke and dementia. Citicoline influences acetylcholine, dopamine, and glutamate neurotransmitter systems; serves as an intermediate in phospholipid metabolism; and enhances the integrity of neuronal membranes. Interest has grown in citicoline as a treatment for addiction since it may have beneficial effects on craving, withdrawal symptoms, and cognitive functioning, as well as the ability to attenuate the neurotoxic effects of drugs of abuse.
OBJECTIVES: To review the literature on citicoline's use in addictive disorders.
METHODS: Using PubMed we conducted a narrative review of the clinical literature on citicoline related to addictive disorders from the years 1900-2013 using the following keywords: citicoline, CDP-choline, addiction, cocaine, alcohol, substance abuse, and substance dependence. Out of approximately 900 first hits, nine clinical studies have been included in this review.
RESULTS: Most addiction research investigated citicoline for cocaine use. The findings suggest that it is safe and well tolerated. Furthermore, citicoline appears to decrease craving and is associated with a reduction in cocaine use, at least at high doses in patients with both bipolar disorder and cocaine dependence. Limited data suggest citicoline may also hold promise for alcohol and cannabis dependence and in reducing food consumption.
CONCLUSIONS: Currently, there is limited research on the efficacy of citicoline for addictive disorders, but the available literature suggests promising results. Future research should employ larger sample sizes, increased dosing, and more complex study designs.

Entities:  

Keywords:  Addiction; alcohol; bipolar disorder; citicoline; cocaine; methamphetamine; substance abuse; substance dependence; substance use

Mesh:

Substances:

Year:  2014        PMID: 24950234      PMCID: PMC4139283          DOI: 10.3109/00952990.2014.925467

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  51 in total

1.  Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice.

Authors:  Weilie Zhang; Masahisa Yamada; Jesus Gomeza; Anthony S Basile; Jürgen Wess
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

2.  Mini-Mental State Examination (MMSE).

Authors:  J R Cockrell; M F Folstein
Journal:  Psychopharmacol Bull       Date:  1988

3.  Effects of short-term citicoline treatment on acute cocaine intoxication and cardiovascular effects.

Authors:  S E Lukas; E M Kouri; C Rhee; A Madrid; P F Renshaw
Journal:  Psychopharmacology (Berl)       Date:  2001-09       Impact factor: 4.530

4.  Effects of cocaine and amphetamine on acetylcholine release in the hippocampus and caudate nucleus.

Authors:  A Imperato; M C Obinu; G L Gessa
Journal:  Eur J Pharmacol       Date:  1993-07-20       Impact factor: 4.432

5.  CDP-choline prevents glutamate-mediated cell death in cerebellar granule neurons.

Authors:  Cecilia Mir; Josep Clotet; Rosa Aledo; Núria Durany; Josep Argemí; Rafael Lozano; Jordi Cervós-Navarro; Núria Casals
Journal:  J Mol Neurosci       Date:  2003-02       Impact factor: 3.444

6.  Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study.

Authors:  S M Babb; L L Wald; B M Cohen; R A Villafuerte; S A Gruber; D A Yurgelun-Todd; P F Renshaw
Journal:  Psychopharmacology (Berl)       Date:  2002-03-22       Impact factor: 4.530

7.  Effects of cytidine-5' diphosphocholine on norepinephrine, dopamine and serotonin synthesis in various regions of the rat brain.

Authors:  M Martinet; P Fonlupt; H Pacheco
Journal:  Arch Int Pharmacodyn Ther       Date:  1979-05

8.  Efficacy of CDP-choline in the treatment of senile alterations in memory.

Authors:  E de la Morena
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

9.  Efficacy and safety of oral CDP-choline. Drug surveillance study in 2817 cases.

Authors:  R Lozano Fernández
Journal:  Arzneimittelforschung       Date:  1983

10.  Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer's disease.

Authors:  J Caamaño; M J Gómez; A Franco; R Cacabelos
Journal:  Methods Find Exp Clin Pharmacol       Date:  1994-04
View more
  8 in total

Review 1.  Possible Benefit and Validity of Supplements for Alcohol Use Disorder.

Authors:  Seungwoo Kang; Doo-Sup Choi
Journal:  Alcohol Clin Exp Res       Date:  2019-03-14       Impact factor: 3.455

2.  Probable Nootropicinduced Psychiatric Adverse Effects: A Series of Four Cases.

Authors:  Farid Talih; Jean Ajaltouni
Journal:  Innov Clin Neurosci       Date:  2015 Nov-Dec

Review 3.  From gene networks to drugs: systems pharmacology approaches for AUD.

Authors:  Laura B Ferguson; R Adron Harris; Roy Dayne Mayfield
Journal:  Psychopharmacology (Berl)       Date:  2018-03-01       Impact factor: 4.530

4.  A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline in Patients with Alcohol Use Disorder.

Authors:  E Sherwood Brown; Erin Van Enkevort; Alexandra Kulikova; Chastity Escalante; Alyson Nakamura; Elena I Ivleva; Traci Holmes
Journal:  Alcohol Clin Exp Res       Date:  2018-12-24       Impact factor: 3.455

5.  Citicoline retards myopia progression following form deprivation in guinea pigs.

Authors:  Junfeng Mao; Shuangzhen Liu; Chunyan Fu
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-14

6.  Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study With a 2-Year Follow-Up.

Authors:  Michele Lanza; Ugo Antonello Gironi Carnevale; Luigi Mele; Mario Bifani Sconocchia; Silvia Bartollino; Ciro Costagliola
Journal:  Front Pharmacol       Date:  2019-09-26       Impact factor: 5.810

Review 7.  Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review.

Authors:  Pascal Valentin Fischler; Michael Soyka; Erich Seifritz; Jochen Mutschler
Journal:  Front Pharmacol       Date:  2022-10-03       Impact factor: 5.988

Review 8.  Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?

Authors:  Khalil Mallah; Christine Couch; Davis M Borucki; Amer Toutonji; Mohammed Alshareef; Stephen Tomlinson
Journal:  Front Immunol       Date:  2020-09-10       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.